Aldeyra Therapeutics(ALDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALDX Aldeyra Therapeutics

Market Closed 09-27 16:00:00 EDT

5.50

+0.13

+2.42%

盘后5.50

+0.000.00%

19:04 EDT

High5.67	Low5.37	Vol509.72K
Open5.44	D1 Closing5.37	Amplitude5.59%
Mkt Cap326.82M	Tradable Cap237.22M	Total Shares59.42M
T/O2.82M	T/O Rate1.18%	Tradable Shares43.13M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ALDX","market":"US","secType":"STK","nameCN":"Aldeyra Therapeutics","latestPrice":5.5,"timestamp":1727467200000,"preClose":5.37,"halted":0,"volume":509722,"hourTrading":{"tag":"盘后","latestPrice":5.5,"preClose":5.5,"latestTime":"19:04 EDT","volume":14193,"amount":78061.449,"timestamp":1727478287451},"delay":0,"floatShares":43131614,"shares":59421551,"eps":-0.639098,"marketStatus":"Market Closed","change":0.13,"latestTime":"09-27 16:00:00 EDT","open":5.44,"high":5.67,"low":5.37,"amount":2815759.377976,"amplitude":0.055866,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.639098,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1727683200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1399003200000,"exchange":"NASDAQ","adjPreClose":5.37,"postHourTrading":{"tag":"盘后","latestPrice":5.5,"preClose":5.5,"latestTime":"19:04 EDT","volume":14193,"amount":78061.449,"timestamp":1727478287451},"volumeRatio":0.9450566969484725,"impliedVol":0.5385,"impliedVolPercentile":0.1468},"requestUrl":"/m/hq/s/ALDX","defaultTab":"news","newsList":[{"id":"2464801268","title":"Aldeyra Therapeutics Announces Executive Team Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2464801268","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2464801268?lang=en_us&edition=fundamental","pubTime":"2024-09-03 21:28","pubTimestamp":1725370138,"startTime":"0","endTime":"0","summary":"An update from Aldeyra Therapeutics (ALDX) is now available. Aldeyra Therapeutics, Inc. has announced the appointment of Michael Alfieri as the new...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aldeyra-therapeutics-announces-executive-team-changes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aldeyra-therapeutics-announces-executive-team-changes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALDX","BK4139","TISI","BK4120"],"gpt_icon":0},{"id":"2463100766","title":"Undercovered Dozen: United Natural Foods, Procter & Gamble, Archer Aviation, Embraer +","url":"https://stock-news.laohu8.com/highlight/detail?id=2463100766","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463100766?lang=en_us&edition=fundamental","pubTime":"2024-08-31 00:30","pubTimestamp":1725035449,"startTime":"0","endTime":"0","summary":"lvenks/iStock via Getty Images Introduction The 'Undercovered' Dozen is a Seeking Alpha editor-curated series highlighting 12 undercovered stock articles from the last week to provide ideas and provoke discussion among the community. Today we're looking at articles published between August 23rd - 29th. Take a look at what these less-covered stocks might hold for you. And please join the conversation below to share what you think: are any of these worth following up on?' one may ask. In the long term, its products are for everyday use and are not accompanied by negative trends. Unlike Coca-Cola  products , PG offers a broad portfolio of products that are and will be a part of our li","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/92246576/image_92246576.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/92246576/image_92246576.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4718161-undercovered-dozen-united-natural-foods-procter-and-gamble-archer-aviation-embraer-plus","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["LU0661504455.SGD","BK4581","LUV","IE0004445239.USD","BK4532","LU1066051498.USD","UAL","BK4533","KRKNF","LU0211327993.USD","LU1914381329.SGD","UNFI","STLA","GMAB","FNMA","IE00BJT1NW94.SGD","LU0256863811.USD","GLPG","LU2108987350.USD","LU2347655156.SGD","BK4157","IMOS","ABBV","BK4534","LU0882574055.USD","LU0237698245.USD","LU0912757837.SGD","FMCC","IE00BJJMRZ35.SGD","LU1023059063.AUD","BK4187","BK4182","PG","LU0061474960.USD","LU0203347892.USD","LU1894683264.USD","ACHR","BK4229","NML","BK4588","ERJ","LU1894683348.USD","IE00BLSP4452.SGD","BK4500","FMCKJ","LU0265550359.USD","NNE","BK4504","ALDX"],"gpt_icon":1},{"id":"2463757889","title":"Aldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case Theory","url":"https://stock-news.laohu8.com/highlight/detail?id=2463757889","media":"Insider Monkey","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463757889?lang=en_us&edition=fundamental","pubTime":"2024-08-30 22:38","pubTimestamp":1725028704,"startTime":"0","endTime":"0","summary":"We came across a bullish thesis on Aldeyra Therapeutics Inc  on ValueInvestorsClub by MrStingy. In this article we will summarize the bulls' thesis on ALDX. Aldeyra Therapeutics shares were trading at $4.15 when this thesis was published, vs. closing price of $5.38 on Aug 29.Despite this promise, Aldeyra faced a setback in November 2023 when the FDA issued a complete response letter , effectively rejecting the company's application for reproxalap’s approval. The FDA required additional trials to demonstrate efficacy on DED symptoms, a hurdle that sent Aldeyra’s stock plummeting by 65%. However, the company has since regrouped, outlining a clear path forward that includes conducting a new Phase 3 trial designed to meet the FDA's criteria. This trial, set in a dry-eye inducing chamber, will focus on ocular discomfort, a key symptom recognized by the FDA. With a robust trial design and strong prior data, the company is optimistic about resubmitting its application later this year.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/nhnRy_j7YXGfgtiBkFTQog--~B/aD0yMjQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/22cc87eeba13d54039473e097b20ef8e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/nhnRy_j7YXGfgtiBkFTQog--~B/aD0yMjQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/22cc87eeba13d54039473e097b20ef8e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aldeyra-therapeutics-inc-nasdaq-aldx-143824760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2210150020.SGD","LU2210149790.SGD","LU0943347566.SGD","BK4112","ALDX","IE00B4R5TH58.HKD","LU0820561909.HKD","ABBV","LU0198837287.USD","IE0002141913.USD","QLD","LU1003077747.HKD","LU1244550221.USD","LU0553294199.USD","LU0689472784.USD","TQQQ","BK4550","LU0170899867.USD","LU0820561818.USD","NDAQ","BK4588","LU0211328371.USD","LU1267930490.SGD","SQQQ","LU0456855351.SGD","CRL","QID","LU0390134368.USD","PSQ","LU2095319765.USD","LU0203345920.USD",".IXIC","BK4585","BK4530","NQmain","IE00B2B36J28.USD","IE0009355771.USD","BK4566","LU1093756325.SGD","LU0310799852.SGD","MNQmain","LU0310800379.SGD","LU0795875169.SGD","LU0114720955.EUR","LU1267930573.SGD","BK4559","IE00BFTCPJ56.SGD","BK4139","LU0985320562.USD"],"gpt_icon":1},{"id":"2463641577","title":"Aldeyra Therapeutics Has Data To Trigger AbbVie Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2463641577","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463641577?lang=en_us&edition=fundamental","pubTime":"2024-08-29 03:49","pubTimestamp":1724874597,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics' Reproxalap eye drop for Dry Eye Disease has new positive data for the second NDA attempt.Aldeyra has an option agreement with AbbVie, potentially leading to significant milestone","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/163674127/image_163674127.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/163674127/image_163674127.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4717708-aldeyra-therapeutics-has-data-to-trigger-abbvie-partnership","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["LU1244550221.USD","LU0456855351.SGD","BK4585","IE00BFTCPJ56.SGD","LU0912757837.SGD","IE0009355771.USD","LU0234570918.USD","BK4534","BK4533","ALDX","BK4566","BK4139","BK4588","LU0310800379.SGD","LU0738911758.USD","LU0795875169.SGD","LU1291159041.SGD","LU0158827948.USD","IE00BSNM7G36.USD","LU0203345920.USD","LU1003077747.HKD","LU0198837287.USD","LU0256863902.USD","LU0545039389.USD","LU0029864427.USD","LU0170899867.USD","IE00B4R5TH58.HKD","LU0820561818.USD","BK4581","LU0114720955.EUR","LU0417517546.SGD","LU1430594728.SGD","LU0689472784.USD","LU0211328371.USD","LU0949170772.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0234572021.USD","LU1023059063.AUD","LU0661504455.SGD","LU0985320562.USD","ABBV","LU1057294990.SGD","LU0795875086.SGD","LU1244550494.USD","LU1244550577.SGD","LU0943347566.SGD","LU0820561909.HKD","LU1267930490.SGD","LU1093756168.USD"],"gpt_icon":0},{"id":"2461590346","title":"Individual investors who hold 37% of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) gained 14%, institutions profited as well","url":"https://stock-news.laohu8.com/highlight/detail?id=2461590346","media":"Simply Wall St.","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461590346?lang=en_us&edition=fundamental","pubTime":"2024-08-22 20:32","pubTimestamp":1724329931,"startTime":"0","endTime":"0","summary":"Key Insights Aldeyra Therapeutics' significant individual investors ownership suggests that the key decisions are...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aldx/aldeyra-therapeutics/news/individual-investors-who-hold-37-of-aldeyra-therapeutics-inc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","QID","SQQQ","ALDX","QLD",".IXIC","TQQQ","LU2095319765.USD","MNQmain","BK4588","NQmain","LU2210150020.SGD","PSQ","BK4112","IE00BKPKM429.USD","BK4139","LU2210149790.SGD","NDAQ"],"gpt_icon":1},{"id":"2459990095","title":"Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), Aldeyra Therapeutics (ALDX) and Immunic (IMUX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2459990095","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459990095?lang=en_us&edition=fundamental","pubTime":"2024-08-13 22:40","pubTimestamp":1723560046,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Xeris Pharmaceuticals (XERS – Research Report), Al...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-xeris-pharmaceuticals-xers-aldeyra-therapeutics-aldx-and-immunic-imux?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-xeris-pharmaceuticals-xers-aldeyra-therapeutics-aldx-and-immunic-imux?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","BK4137","XERS","IMUX","HCSG","ALDX"],"gpt_icon":0},{"id":"2458956450","title":"Aldeyra Therapeutics: A Buy Rating on Strong Clinical Progress and Market Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2458956450","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458956450?lang=en_us&edition=fundamental","pubTime":"2024-08-09 19:52","pubTimestamp":1723204369,"startTime":"0","endTime":"0","summary":"BTIG analyst Thomas Shrader has maintained their bullish stance on ALDX stock, giving a Buy rating today. Thomas Shrader’s rating is based on a com...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/aldeyra-therapeutics-a-buy-rating-on-strong-clinical-progress-and-market-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/aldeyra-therapeutics-a-buy-rating-on-strong-clinical-progress-and-market-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALDX","PRGS"],"gpt_icon":0},{"id":"2458855034","title":"Aldeyra Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2458855034","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458855034?lang=en_us&edition=fundamental","pubTime":"2024-08-09 18:14","pubTimestamp":1723198440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 09, 2024 06:14 ET (10:14 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX"],"gpt_icon":0},{"id":"2458537075","title":"Aldeyra Therapeutics Inc : Jefferies Raises Target Price to $8 From $7","url":"https://stock-news.laohu8.com/highlight/detail?id=2458537075","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458537075?lang=en_us&edition=fundamental","pubTime":"2024-08-09 15:39","pubTimestamp":1723189180,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240809:nFWN3JV2B3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALDX","BK4139"],"gpt_icon":0},{"id":"2458834329","title":"Aldeyra climbs after late-stage success for dry eye disease therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2458834329","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458834329?lang=en_us&edition=fundamental","pubTime":"2024-08-09 00:26","pubTimestamp":1723134410,"startTime":"0","endTime":"0","summary":"Shares of Aldeyra Therapeutics  surged ~26% on Thursday after the company said its lead asset, reproxalap ophthalmic solution, reached the main goal in a Phase 3 trial for patients with dry eye disease. Aldeyra  ran the trial after the FDA rejected its marketing application for reproxalap in November, citing the need for “at least one additional adequate and well-controlled study” to demonstrate its clinical benefits against dry eye disease symptoms. The company said reproxalap reached the primary endpoint for ocular discomfort, the FDA-accepted symptom of dry eye disease, indicating statistical superiority against a comparator. There were no new safety signals, and the experimental therapy was well tolerated. ALDX added. The company said it intends to resubmit its new drug application for reproxalap in 2024 and expects the agency’s review period to last six months. In November, pharma giant AbbVie  inked an option agreement to obtain commercial rights for reproxalap.","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/147009250/image_147009250.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/147009250/image_147009250.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4137394-aldeyra-stock-climbs-after-trial-success","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["LU1244550221.USD","LU0128525929.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU1003077747.HKD","BK4588","LU0310800379.SGD","LU0234570918.USD","LU0234572021.USD","LU0795875086.SGD","LU1061106388.HKD","ALDX","IE0002141913.USD","LU0417517546.SGD","LU0553294199.USD","LU0661504455.SGD","LU0708994859.HKD","LU0882574055.USD","LU1496350171.SGD","BK4566","LU1291159041.SGD","LU1430594728.SGD","LU1267930573.SGD","BK4533","IE0004445239.USD","BK4559","ABBV","LU1093756325.SGD","LU0211328371.USD","LU0795875169.SGD","LU0943347566.SGD","LU0211327993.USD","LU0545039389.USD","LU0738911758.USD","LU0820561909.HKD","BK4581","LU0029864427.USD","LU0158827948.USD","LU0912757837.SGD","BK4139","LU0122379950.USD","LU1093756168.USD","LU1267930490.SGD","LU1023059063.AUD","IE00BSNM7G36.USD","LU0198837287.USD","LU0456855351.SGD","LU1244550577.SGD","LU0114720955.EUR","BK4585"],"gpt_icon":0},{"id":"2457397294","title":"Aldeyra Therapeutics Shares Rise 9.2% on Trial Outcome for Dry Eye Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2457397294","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457397294?lang=en_us&edition=fundamental","pubTime":"2024-08-08 20:24","pubTimestamp":1723119840,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics shares were up 9.2% in premarket trading after achieving the primary endpoint in a Phase 3 clinical trial of a dry eye disease treatment.Shares were recently trading around $3.56. The stock is down 7.1% on the year.The biotechnology company said Reproxalap was statistically superior to vehicle for the prespecified primary endpoint of ocular discomfort, a Food and Drug Administration accepted symptom of dry eye disease.Aldeyra said the trial was designed to satisfy the FDA's new drug application resubmission requirement, which is expected to take place this year. The review period by the FDA is expected to be six months.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX","BK4139"],"gpt_icon":0},{"id":"2457039292","title":"BUZZ-Aldeyra rises as eye disease therapy meets late-stage study goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2457039292","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457039292?lang=en_us&edition=fundamental","pubTime":"2024-08-08 20:08","pubTimestamp":1723118912,"startTime":"0","endTime":"0","summary":"** Shares of drug developer Aldeyra Therapeutics    rise 10.4% to $3.60 premarket    ** Co says its experimental therapy to treat dry eye disease met the main goal of a late-stage study   ** Dry eye disease affects the layers of tears that cover the cornea causing symptoms like burning, itching and blurred vision    ** Co says the therapy reproxalap was statistically superior in reducing the symptom of ocular discomfort in patients    ** Trial was designed to satisfy the U.S. FDA's marketing application resubmission requirement - co    ** No safety signals were observed in the clinical trial, and reproxalap was well tolerated- ALDX    ** The FDA last year rejected the therapy as it did not demonstrate efficacy in treating symptoms of the disease   ** Up to last close, stock down 7.1% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BUZZ","ALDX"],"gpt_icon":0},{"id":"2457139959","title":"Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap","url":"https://stock-news.laohu8.com/highlight/detail?id=2457139959","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457139959?lang=en_us&edition=fundamental","pubTime":"2024-08-08 19:00","pubTimestamp":1723114800,"startTime":"0","endTime":"0","summary":"LEXINGTON, Mass., August 08, 2024----Aldeyra Therapeutics, Inc.  , a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the achievement of the primary endpoint in a Phase 3 randomized, double-masked, vehicle-controlled dry eye chamber clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate, for the treatment of dry eye disease. Reproxalap was statistically superior to vehicle for the prespecified primary endpoint of ocular discomfort , a U.S. Food and Drug Administration -accepted symptom of dry eye disease.\"To our knowledge, the results announced today represent the first positive Phase 3 clinical trial in a dry eye chamber with a symptom as a primary endpoint, and we believe that the results are supportive of the potential rapid clinical effect of reproxalap on reducing the ocular discomfort associated with dry eye disease,\" stated Todd C. Brad","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UBWRqORGS9TKQD528qQoWg--~B/aD0yNzA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/23ce0625ae68d499fe8389a1f0119b53","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UBWRqORGS9TKQD528qQoWg--~B/aD0yNzA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/23ce0625ae68d499fe8389a1f0119b53"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aldeyra-therapeutics-achieves-primary-endpoint-110000999.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2457877339","title":"Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap","url":"https://stock-news.laohu8.com/highlight/detail?id=2457877339","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457877339?lang=en_us&edition=fundamental","pubTime":"2024-08-08 04:01","pubTimestamp":1723060860,"startTime":"0","endTime":"0","summary":"LEXINGTON, Mass., August 07, 2024----Aldeyra Therapeutics, Inc.   today announced it will host a webcast and conference call on Thursday, August 8, 2024, at 9:00 a.m.  to provide top-line results from the Phase 3 dry eye disease clinical trial of reproxalap.The dial-in numbers are  596-4144 for domestic callers and  968-2525 for international callers. The access code is 7321123. A live audio webcast of the conference call also will be accessible from the \"Investors & Media\" section of Aldeyra's website at ir.aldeyra.com.After the live webcast, the event will remain archived on Aldeyra’s website for 90 days.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aldeyra-therapeutics-schedules-conference-call-200100368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4581","BK4139","BK4590","BK4144","ALDX","BK4588","ET","BK4585","BK4561"],"gpt_icon":0},{"id":"2457744850","title":"Buy Rating on Aldeyra Therapeutics Backed by Strong Drug Pipeline and Lead Candidate’s Market Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2457744850","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457744850?lang=en_us&edition=fundamental","pubTime":"2024-08-07 13:28","pubTimestamp":1723008514,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Marc Goodman reiterated a Buy rating on Aldeyra Therapeutics (ALDX – Research Report) on August 5 and set a price target o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-on-aldeyra-therapeutics-backed-by-strong-drug-pipeline-and-lead-candidates-market-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-on-aldeyra-therapeutics-backed-by-strong-drug-pipeline-and-lead-candidates-market-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALDX"],"gpt_icon":0},{"id":"2456940049","title":"Aldeyra Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2456940049","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2456940049?lang=en_us&edition=fundamental","pubTime":"2024-08-02 20:25","pubTimestamp":1722601500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 02, 2024 08:25 ET (12:25 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX"],"gpt_icon":0},{"id":"2456477408","title":"Buy Rating Affirmed for Aldeyra Therapeutics Amid Promising Drug Trials and Broad RASP Platform Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2456477408","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2456477408?lang=en_us&edition=fundamental","pubTime":"2024-08-02 18:26","pubTimestamp":1722594368,"startTime":"0","endTime":"0","summary":"Matthew Caufield, an analyst from H.C. Wainwright, reiterated the Buy rating on Aldeyra Therapeutics (ALDX – Research Report). The associated price...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-aldeyra-therapeutics-amid-promising-drug-trials-and-broad-rasp-platform-prospects?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-aldeyra-therapeutics-amid-promising-drug-trials-and-broad-rasp-platform-prospects?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RASP","ALDX"],"gpt_icon":0},{"id":"2456946767","title":"Aldeyra Therapeutics Inc: Entered Sales Agreement to Sell up to $75 Mln Shares of Common Stock- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2456946767","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2456946767?lang=en_us&edition=fundamental","pubTime":"2024-08-02 05:01","pubTimestamp":1722546094,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240801:nFWN3JO1UI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALDX"],"gpt_icon":0},{"id":"2455364136","title":"Owning 36% shares,institutional owners seem interested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX),","url":"https://stock-news.laohu8.com/highlight/detail?id=2455364136","media":"Simply Wall St.","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2455364136?lang=en_us&edition=fundamental","pubTime":"2024-07-31 21:01","pubTimestamp":1722430894,"startTime":"0","endTime":"0","summary":"Significantly high institutional ownership implies Aldeyra Therapeutics' stock price is sensitive to their trading actions. A total of 12 investors have a majority stake in the company with 50% ownership. Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company. A look at the shareholders of Aldeyra Therapeutics, Inc.  can tell us which group is most powerful. The group holding the most number of shares in the company, around 36% to be precise, is institutions. That is, the group stands to benefit the most if the stock rises .Let's take a closer look to see what the different types of shareholders can tell us about Aldeyra Therapeutics.Check out our latest analysis for Aldeyra Therapeutics. While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seei","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/owning-36-shares-institutional-owners-130134280.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALDX","LU2095319765.USD","NQmain","IE00BKPKM429.USD","QID","LU2210149790.SGD","BK4588","TQQQ","MNQmain","QLD",".IXIC","NDAQ","BK4139","BK4585","PSQ","SQQQ","LU2210150020.SGD","BK4112"],"gpt_icon":1},{"id":"2455948664","title":"Aldeyra Therapeutics Inc    expected to post a loss of 15 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2455948664","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2455948664?lang=en_us&edition=fundamental","pubTime":"2024-07-31 09:34","pubTimestamp":1722389656,"startTime":"0","endTime":"0","summary":"* Aldeyra Therapeutics Inc     is expected to show no change in quarterly revenue when it reports  results on August 1 (estimated) for the period ending January 1 0001   *    * LSEG's mean analyst est","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aldeyra.com","stockEarnings":[{"period":"1week","weight":-0.0662},{"period":"1month","weight":0.0476},{"period":"3month","weight":0.6616},{"period":"6month","weight":0.682},{"period":"1year","weight":-0.1214},{"period":"ytd","weight":0.567}],"compareEarnings":[{"period":"1week","weight":0.0056},{"period":"1month","weight":0.0235},{"period":"3month","weight":0.05},{"period":"6month","weight":0.0924},{"period":"1year","weight":0.3335},{"period":"ytd","weight":0.2022}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.077344},{"month":2,"riseRate":0.6,"avgChangeRate":0.000014},{"month":3,"riseRate":0.4,"avgChangeRate":-0.001859},{"month":4,"riseRate":0.5,"avgChangeRate":0.045254},{"month":5,"riseRate":0.4,"avgChangeRate":0.032473},{"month":6,"riseRate":0.272727,"avgChangeRate":-0.035553},{"month":7,"riseRate":0.545455,"avgChangeRate":0.029811},{"month":8,"riseRate":0.454545,"avgChangeRate":0.039547},{"month":9,"riseRate":0.545455,"avgChangeRate":0.196609},{"month":10,"riseRate":0.5,"avgChangeRate":-0.105045},{"month":11,"riseRate":0.7,"avgChangeRate":0.094222},{"month":12,"riseRate":0.4,"avgChangeRate":-0.034658}],"exchange":"NASDAQ","name":"Aldeyra Therapeutics","nameEN":"Aldeyra Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.2","shortVersion":"4.28.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aldeyra Therapeutics(ALDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aldeyra Therapeutics(ALDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aldeyra Therapeutics,ALDX,Aldeyra Therapeutics股票,Aldeyra Therapeutics股票老虎,Aldeyra Therapeutics股票老虎国际,Aldeyra Therapeutics行情,Aldeyra Therapeutics股票行情,Aldeyra Therapeutics股价,Aldeyra Therapeutics股市,Aldeyra Therapeutics股票价格,Aldeyra Therapeutics股票交易,Aldeyra Therapeutics股票购买,Aldeyra Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aldeyra Therapeutics(ALDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aldeyra Therapeutics(ALDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}